Indolent Systemic Mastocytosis
Oncology·MeSH: Mastocytosis
Prevalence
30.0 / 100K
2 drugs in development·1 company·4 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| elenestinib | Blueprint Medicines Corp (BPMC) |
Phase 4(1)
| Drug | Company |
|---|---|
| avapritinib | Blueprint Medicines Corp (BPMC) |
Compare drugs
Frequently asked questions
How many drugs are in development for Indolent Systemic Mastocytosis?
BioSniper tracks 2 drugs in development for Indolent Systemic Mastocytosis across 1 company.
How many clinical trials target Indolent Systemic Mastocytosis?
There are 4 clinical trials targeting Indolent Systemic Mastocytosis tracked by BioSniper.
What is the prevalence of Indolent Systemic Mastocytosis?
The estimated prevalence of Indolent Systemic Mastocytosis is approximately 30.0 per 100,000 population.
Deep-dive into Indolent Systemic Mastocytosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis